In patients with HIV-related EBV-SMT, HAART is necessary to prevent opportunistic infections, and due to the promising treatment effect in congenital immunodeficiency- and post-transplant-related EBV-SMTs, it also suggested that secondary increased CD4 counts can assist in the treatment of HIV-related EBV-SMTs. This evidence concerns the gene CD4 and Opportunistic infection.